Progenics Pharmaceuticals Inc. (PGNX)

6.16
NASDAQ : Health Technology
Prev Close 6.07
Day Low/High 5.98 / 6.17
52 Wk Low/High 4.60 / 11.72
Avg Volume 1.13M
Exchange NASDAQ
Shares Outstanding 70.27M
Market Cap 410.38M
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Reversal Offers Chance in 2 Small Biotechs

Reversal Offers Chance in 2 Small Biotechs

I've added to my positions in these names on yesterday's intraday silliness.

First Week Of PGNX August 2018 Options Trading

First Week Of PGNX August 2018 Options Trading

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the August 2018 expiration.

3 Tiny Explosive Biotech Stocks for 2018

3 Tiny Explosive Biotech Stocks for 2018

Sector M&A activity is likely to pick up next year benefiting the space.

Oversold Conditions For Progenics Pharmaceuticals (PGNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

4 Small-Caps on My Earnings Watch List

4 Small-Caps on My Earnings Watch List

We are coming my favorite part of earnings season -- when these small-caps report.

Housing Stocks Will See Demand Boost

Housing Stocks Will See Demand Boost

The housing market will continue to improve over the next few years due to pent up demand.

Don't Panic About Biotech

Don't Panic About Biotech

Diversification is absolutely critical when investing in this sector.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.

Which Stocks Have Changed Direction?

Which Stocks Have Changed Direction?

Finding bullish and bearish reversals in the market.

These 4 Small Biotechs Have Big Upcoming Catalysts

These 4 Small Biotechs Have Big Upcoming Catalysts

Zogenix, Flexion, Dynavax and Progenics all have potential upside on these events.

4 Small Biotechs With Big Catalysts

4 Small Biotechs With Big Catalysts

Zogenix, Flexion, Dynavax and Progenics all have potential upside on upcoming events.

Progenics Pharmaceuticals Presents Data From AZEDRA® Pivotal Phase 2b Study At The 5th International Symposium On Pheochromocytoma And Paraganglioma

Progenics Pharmaceuticals Presents Data From AZEDRA® Pivotal Phase 2b Study At The 5th International Symposium On Pheochromocytoma And Paraganglioma

Study results show that treatment with AZEDRA produced clinically meaningful and durable responses across multiple study endpoints, including radiographic tumor response, tumor biomarker response, and overall survival

TheStreet Quant Rating: D (Sell)